US2018344734A1PendingUtilityA1

Inhibitors of beta-secretase

58
Assignee: VITAE PHARMACEUTICALS INCPriority: Mar 5, 2012Filed: Mar 12, 2018Published: Dec 6, 2018
Est. expiryMar 5, 2032(~5.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 27/06A61P 25/28A61P 25/16A61P 27/02A61P 25/00C07D 403/06C07D 405/06C07D 235/02C07C 49/747A61K 31/4184C07C 313/06C07C 255/47C07D 407/06C07C 49/697C07C 2603/94C07C 331/14A61K 31/506C07C 229/50C07D 405/04C07C 49/755
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound having the following structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.